# Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

> **NCT06207734** · PHASE2 · RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Continuation of CDK4/6 inhibitor Palbociclib
- **DRUG:** Discontinuation of CDK4/6 inhibitor Palbociclib
- **DRUG:** Continuation of CDK4/6 inhibitor -Palbociclib
- **DRUG:** Discontinuation of CDK4/6 inhibitor -Palbociclib
- **DRUG:** Continuation of CDK4/6 inhibitor Abemaciclib
- **DRUG:** Discontinuation of CDK4/6 inhibitor Abemaciclib

## Key facts

- **NCT ID:** NCT06207734
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-17
- **Primary completion:** 2027-01-10
- **Final completion:** 2028-07-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06207734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06207734, "Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06207734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*